相关临床试验
2285
2224 进行中
药物批准
16
批准总数
监管机构
3
监管机构数
成立时间
N/A
招募中
22
1.0%
进行中（未招募）
2217
97.0%
Unknown
1
0.0%
已完成
38
1.7%
尚未招募
7
0.3%
- The global urinalysis market is projected to grow from USD 4.88 billion in 2026 to USD 7.16 billion by 2031, at a compound annual growth rate (CAGR) of 8.0%. - The consumables segment held the largest market share at 72.5% in 2025, while pregnancy and fertility tests led test types with a 42.8% share. - North America remains the largest regional market, with Asia Pacific expected to register the fastest growth during the forecast period. - Growth is driven by rising prevalence of urinary tract infections, diabetes, and kidney and liver diseases, alongside increasing adoption of automated and point-of-care testing.
- The global epigenomics market is projected to grow from US$16.9 billion in 2024 to US$69.6 billion by 2034, a 15.2% CAGR. - Oncology dominates applications with a 57.2% share, while DNA methylation leads the technology segment at 48.1% of revenue. - More than 10 epigenetic drugs are approved and over 35 epigenetic therapies are in clinical trials worldwide, signaling expanding therapeutic investment. - North America holds a leading 41.3% market share, with Asia-Pacific forecast to record the fastest growth through 2034.
- The global body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, at a CAGR of 6.9%. - Consumables dominated the market with a 70.4% share in 2025, while immunoassay technology is expected to register the highest growth rate during the forecast period. - Cerebrospinal fluid analysis led the market by fluid type at 29.1% share in 2025, driven by expanding neurological disease evaluation and biomarker-based testing. - North America held the largest regional market share in 2025, while Asia Pacific is expected to be the fastest-growing region through 2031.
- The global antibody therapeutics market was valued at US$ 266.9 billion in 2024 and is projected to reach US$ 737.6 billion by 2034, growing at a CAGR of 10.7%. - Monoclonal antibodies dominated the market with a 62.7% share in 2024, while the oncology segment accounted for 58.4% of total revenue. - North America led the global market with a 41.8% share in 2024, while Asia Pacific is expected to register the fastest growth during the forecast period. - Advancements in AI-driven antibody discovery, bispecific antibodies, and antibody-drug conjugates are expanding therapeutic applications across cancer, autoimmune, and neurological disorders.
- A new AI model called COMPASS, developed by Harvard Medical School researchers, improves prediction of which patients will respond to immune checkpoint inhibitors by 8.5% over existing approaches. - The model analyzes nearly 16,000 genes related to immune cell states and tumor-microenvironment interactions, providing interpretable rationale for its predictions rather than black-box outputs. - COMPASS was trained on data from 10,184 tumors across 33 cancer types and fine-tuned using results from 16 clinical trials spanning seven cancer types. - If validated in prospective clinical trials, COMPASS could guide personalized treatment decisions, improve clinical trial enrollment, and generate new drug target hypotheses.
- Chugai Pharmaceutical has secured exclusive Japanese rights to CT-388, a long-acting dual GLP-1/GIP receptor agonist being developed for obesity and type 2 diabetes treatment. - Phase I clinical trial results showed CT-388 achieved an impressive placebo-adjusted mean weight reduction of 18.8% at 24 weeks with 100% of participants achieving >5% weight loss. - The drug demonstrated excellent tolerability with mostly mild to moderate gastrointestinal side effects typical of incretin-based therapies, and is currently advancing to Phase II trials overseas.
- RESTEM, a clinical-stage biotech company, received FDA Orphan Drug Designation in December 2024 for its umbilical cord outer lining stem cell program targeting polymyositis and dermatomyositis. - The polymyositis therapeutic pipeline includes over 7 companies developing treatments, with emerging therapies like HuABC2, PF1801, PN-101, and M5049 advancing through clinical trials. - Polymyositis is a rare autoimmune disease causing inflammation and weakness of skeletal muscles, with current treatment options limited and high drug costs creating market barriers.
- A comprehensive 2025 clinical trials review reveals the current global research landscape for alopecia universalis, analyzing trial distribution across regions, phases, and sponsor types. - Major pharmaceutical companies including Pfizer, Johnson & Johnson, Roche, and Aclaris Therapeutics are actively participating in alopecia universalis therapeutic development programs. - The report provides critical insights into trial enrollment trends over the past five years and identifies prominent drugs currently in development for this severe autoimmune hair loss condition. - Clinical trial data is compiled from over 80 different registries worldwide, offering stakeholders comprehensive market intelligence for strategic decision-making in dermatology therapeutics.
- The Supreme Court of India has issued a notice to F. Hoffmann-La Roche Ltd regarding the pricing of Risdiplam, a medication for Spinal Muscular Atrophy (SMA), questioning why it's more expensive in India than neighboring countries. - The case involves a 24-year-old woman with SMA who challenged the high cost of treatment, with her counsel arguing that government intervention in Pakistan and China has made the same medication more affordable in those countries. - The Court has requested information on Risdiplam pricing in neighboring countries and whether the drug manufacturer would consider supplying it at lower rates in India, with the next hearing scheduled for April 8.
- Neurocrine Biosciences has appointed Dr. Sanjay Keswani as Chief Medical Officer effective June 2, 2025, succeeding Dr. Eiry W. Roberts who served in the role for seven years. - Dr. Keswani brings over 20 years of pharmaceutical industry experience as a physician-scientist with expertise across multiple therapeutic areas and will lead clinical development and medical affairs activities. - Prior to joining Neurocrine, Dr. Keswani served as President and CEO of ImmunoBrain and held senior leadership positions at Hoffman La Roche and Bristol-Myers Squibb.
